FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005016941> ?p ?o ?g. }

• W2005016941 endingPage "681" @default.
• W2005016941 startingPage "675" @default.
• W2005016941 abstract "Aim: To test for immunologic noninferiority of antibody responses to Hib and MenC using a 6-in-1 combination vaccine (DTPa-IPV/Hib-MenC-TT) compared with DTPa-IPV-Hib plus MenC-CRM197, before and after a 12-month Hib-MenC-TT booster. Methods: Pragmatic open-label, randomized, multicenter, UK study. “6-in-1” group received DTPa-IPV/Hib-MenC-TT at 2, 3 and 4 months; control group received DTPa-IPV-Hib at 2, 3 and 4 months and MenC-CRM197 at 3 and 4 months. Both groups received Hib-MenC-TT at 12 months. Concomitant vaccines: pneumococcal conjugate vaccine at 2, 4 and 13 months, and measles, mumps and rubella vaccine at 13 months. Results: One hundred forty-two children were randomized to each group. One hundred children in the “6-in-1” group and 112 control group children completed the study according-to-protocol. One month postprimary immunizations: 100% of “6-in-1” group and 93.3% of control children had anti–polyribosylribitol phosphate (PRP) IgG ≥0.15 µg/mL; 96.2% and 100%, respectively, had rSBA-MenC titers ≥1:8. One month after booster all children met these thresholds, with anti-PRP geometric mean concentrations of 66.7 (53.3; 83.5) in “6-in-1” recipients and 26.9 (20.9; 34.6) in control children (4.4 [3.5; 5.4] and 3.0 [2.2–4.2] postprimary immunizations, respectively,). rSBA-MenC geometric mean titers were 3062.9 (2421.2; 3874.6) and 954.0 (761.3; 1195.5), respectively, postbooster and 393.2 (292.5; 528.7) and 3110.5 (2612; 3704.2) postprimary. Conclusion: Noninferiority of DTPa-IPV/Hib-MenC-TT compared with DTPa-IPV/Hib plus MenC-CRM197 was demonstrated. In the “6-in-1” group, lower postprimary and greater postbooster rSBA-MenC geometric mean titers suggest memory B-cell priming may be favored by this vaccine over plasma cell induction. Furthermore, greater immunogenicity of TT conjugates used in both primary and booster vaccines in this group may be important." @default.
• W2005016941 created "2016-06-24" @default.
• W2005016941 creator A5002706321 @default.
• W2005016941 creator A5006772052 @default.
• W2005016941 creator A5021754699 @default.
• W2005016941 creator A5030730584 @default.
• W2005016941 creator A5034393834 @default.
• W2005016941 creator A5035296750 @default.
• W2005016941 creator A5042958777 @default.
• W2005016941 creator A5042985536 @default.
• W2005016941 creator A5045695482 @default.
• W2005016941 creator A5046673368 @default.
• W2005016941 creator A5053631507 @default.
• W2005016941 creator A5065914659 @default.
• W2005016941 creator A5073745658 @default.
• W2005016941 creator A5088018772 @default.
• W2005016941 creator A5088821917 @default.
• W2005016941 creator A5090994672 @default.
• W2005016941 date "2013-06-01" @default.
• W2005016941 modified "2023-09-26" @default.
• W2005016941 title "Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy Infants" @default.
• W2005016941 cites W1933668405 @default.
• W2005016941 cites W1969590818 @default.
• W2005016941 cites W1983341667 @default.
• W2005016941 cites W1991226916 @default.
• W2005016941 cites W2006750738 @default.
• W2005016941 cites W2023060733 @default.
• W2005016941 cites W2027445502 @default.
• W2005016941 cites W2030178991 @default.
• W2005016941 cites W2030785840 @default.
• W2005016941 cites W2033366028 @default.
• W2005016941 cites W2039120617 @default.
• W2005016941 cites W2049865589 @default.
• W2005016941 cites W2071047927 @default.
• W2005016941 cites W2075892057 @default.
• W2005016941 cites W2079081917 @default.
• W2005016941 cites W2091356778 @default.
• W2005016941 cites W2096913021 @default.
• W2005016941 cites W2098917747 @default.
• W2005016941 cites W2107886759 @default.
• W2005016941 cites W2114663173 @default.
• W2005016941 cites W2117129745 @default.
• W2005016941 cites W2124912532 @default.
• W2005016941 cites W2128589740 @default.
• W2005016941 cites W2134945394 @default.
• W2005016941 cites W2137053577 @default.
• W2005016941 cites W2137591261 @default.
• W2005016941 cites W2139565340 @default.
• W2005016941 cites W2139883634 @default.
• W2005016941 cites W2143988954 @default.
• W2005016941 cites W2144137490 @default.
• W2005016941 cites W2156776857 @default.
• W2005016941 cites W2159483543 @default.
• W2005016941 cites W2160879811 @default.
• W2005016941 cites W2167668039 @default.
• W2005016941 cites W2169803204 @default.
• W2005016941 cites W2315341791 @default.
• W2005016941 cites W2325085154 @default.
• W2005016941 doi "https://doi.org/10.1097/inf.0b013e31828672a7" @default.
• W2005016941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23348809" @default.
• W2005016941 hasPublicationYear "2013" @default.
• W2005016941 type Work @default.
• W2005016941 sameAs 2005016941 @default.
• W2005016941 citedByCount "4" @default.
• W2005016941 countsByYear W20050169412015 @default.
• W2005016941 countsByYear W20050169412016 @default.
• W2005016941 countsByYear W20050169412018 @default.
• W2005016941 crossrefType "journal-article" @default.
• W2005016941 hasAuthorship W2005016941A5002706321 @default.
• W2005016941 hasAuthorship W2005016941A5006772052 @default.
• W2005016941 hasAuthorship W2005016941A5021754699 @default.
• W2005016941 hasAuthorship W2005016941A5030730584 @default.
• W2005016941 hasAuthorship W2005016941A5034393834 @default.
• W2005016941 hasAuthorship W2005016941A5035296750 @default.
• W2005016941 hasAuthorship W2005016941A5042958777 @default.
• W2005016941 hasAuthorship W2005016941A5042985536 @default.
• W2005016941 hasAuthorship W2005016941A5045695482 @default.
• W2005016941 hasAuthorship W2005016941A5046673368 @default.
• W2005016941 hasAuthorship W2005016941A5053631507 @default.
• W2005016941 hasAuthorship W2005016941A5065914659 @default.
• W2005016941 hasAuthorship W2005016941A5073745658 @default.
• W2005016941 hasAuthorship W2005016941A5088018772 @default.
• W2005016941 hasAuthorship W2005016941A5088821917 @default.
• W2005016941 hasAuthorship W2005016941A5090994672 @default.
• W2005016941 hasBestOaLocation W20050169411 @default.
• W2005016941 hasConcept C12590561 @default.
• W2005016941 hasConcept C126322002 @default.
• W2005016941 hasConcept C138496976 @default.
• W2005016941 hasConcept C15744967 @default.
• W2005016941 hasConcept C159654299 @default.
• W2005016941 hasConcept C187212893 @default.
• W2005016941 hasConcept C203014093 @default.
• W2005016941 hasConcept C22070199 @default.
• W2005016941 hasConcept C2776438120 @default.
• W2005016941 hasConcept C2778242525 @default.
• W2005016941 hasConcept C2779384505 @default.
• W2005016941 hasConcept C2779583294 @default.
• W2005016941 hasConcept C2779592421 @default.

• next